Business Context and Reporting Period
HeartCore Enterprises, Inc. filed this Form 8-K on May 30, 2023, reporting an agreement entered into on May 29, 2023. The company is a Delaware corporation headquartered in Tokyo, Japan, with common stock listed on Nasdaq under the symbol HTCR.
Material Financing Transaction
- HeartCore entered into a Common Stock Sales Agreement with Sutter Securities, Inc. to issue and sell up to $5.0 million of common stock from time to time.
- Sales may occur through an “at-the-market” offering under the company’s effective shelf registration statement, File No. 333-270503, declared effective April 12, 2023.
- The company stated that it would file a prospectus supplement covering the offering.
- The filing does not state the number of shares to be issued, the offering price, the amount sold as of the filing date, or the net proceeds received.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, cash balances, liquidity ratios, or other operating financial metrics. The offering is intended to provide access to additional equity capital, but the filing does not specify the use of proceeds.
Material Changes, Outlook, and Risks
- No operating results or guidance changes are reported.
- Issuance of common stock could dilute existing shareholders; the extent of potential dilution cannot be determined from the filing because the number and timing of shares are unspecified.
- Sutter Securities may terminate the agreement upon specified events, including a material adverse change, certain company defaults, failure of conditions, trading suspensions or limitations, market disruptions, or exchange price restrictions.
- Either party may terminate the agreement at its discretion with 10 days’ notice.
- The agreement automatically terminates upon the earlier sale of all placement shares or expiration of the shelf registration statement, which is generally expected three years after its initial effectiveness under Rule 415(a)(5), unless otherwise terminated earlier.
- The offering remains subject to the applicable registration statement, prospectus, prospectus supplement, market conditions, and Nasdaq requirements.
Key Facts for Investors to Verify
- Whether any shares have been sold and the remaining availability under the $5.0 million offering.
- The actual sales prices, commissions, expenses, and net proceeds received.
- The intended use of proceeds and whether the financing addresses near-term liquidity needs.
- The potential effect of issued shares on ownership dilution and Nasdaq listing compliance.
- The final prospectus supplement and the complete Common Stock Sales Agreement filed as Exhibit 10.1.